Showing results (1-10 of 251) with videos related to
Sort By:
Pageof 26
Japanese Journal of Clinical Oncology|December 7, 2014
Implementation status and explanatory analysis of early advance care planning for Stage IV non-small cell lung cancer patientsTakaaki Tokito, Haruyasu Murakami, Keita Mori, et al.Cancer Chemotherapy and Pharmacology|December 3, 2010
Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patientsToshiaki Takahashi, Yukiko Nakamura, Asuka Tsuya, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2005
Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancerHaruyasu Murakami, Akihito Yokoyama, Keiichi Kondo, et al.Cancer Science|April 5, 2014
Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cellsMasakuni Serizawa, Haruyasu Murakami, Masaru Watanabe, et al.Cancer Chemotherapy and Pharmacology|July 31, 2015
A Phase I study of MEDI-575, a PDGFRα monoclonal antibody, in Japanese patients with advanced solid tumorsHaruyasu Murakami, Masafumi Ikeda, Takuji Okusaka, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 21, 2009
[Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients]Yasukata Ohashi, Kenichi Suzuki, Michiru Sakurai, et al.Cancer Chemotherapy and Pharmacology|August 3, 2010
Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumorsYutaka Ueda, Tatsu Shimoyama, Haruyasu Murakami, et al.Cancer Chemotherapy and Pharmacology|May 8, 2007
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumorsNoboru Yamamoto, Atsushi Horiike, Yasuhito Fujisaka, et al.Investigational New Drugs|February 18, 2018
A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumorsHideki Ueno, Shunsuke Kondo, Shusuke Yoshikawa, et al.Cancer Chemotherapy and Pharmacology|August 3, 2010
Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumorsHaruyasu Murakami, Yutaka Ueda, Tatsu Shimoyama, et al.Pageof 26